Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Bought by Holocene Advisors LP

Holocene Advisors LP lifted its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 65.0% during the third quarter, Holdings Channel reports. The firm owned 97,447 shares of the company’s stock after acquiring an additional 38,405 shares during the quarter. Holocene Advisors LP’s holdings in Denali Therapeutics were worth $2,839,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Victory Capital Management Inc. increased its position in Denali Therapeutics by 163.7% during the third quarter. Victory Capital Management Inc. now owns 39,900 shares of the company’s stock worth $1,162,000 after buying an additional 24,767 shares during the period. Candriam S.C.A. increased its holdings in shares of Denali Therapeutics by 62.2% in the 2nd quarter. Candriam S.C.A. now owns 726,499 shares of the company’s stock valued at $16,869,000 after acquiring an additional 278,621 shares during the period. Integral Health Asset Management LLC acquired a new position in shares of Denali Therapeutics in the 2nd quarter valued at $7,546,000. FMR LLC raised its position in Denali Therapeutics by 3,234.3% in the 3rd quarter. FMR LLC now owns 7,831,378 shares of the company’s stock valued at $228,128,000 after purchasing an additional 7,596,508 shares during the last quarter. Finally, Algert Global LLC boosted its stake in Denali Therapeutics by 82.4% during the 3rd quarter. Algert Global LLC now owns 48,630 shares of the company’s stock worth $1,417,000 after purchasing an additional 21,975 shares during the period. 92.92% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Denali Therapeutics

In other Denali Therapeutics news, Director Steve E. Krognes sold 30,000 shares of the firm’s stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $29.03, for a total transaction of $870,900.00. Following the sale, the director now directly owns 29,096 shares of the company’s stock, valued at $844,656.88. This trade represents a 50.76 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Vicki L. Sato sold 1,020 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $30.00, for a total transaction of $30,600.00. Following the completion of the transaction, the director now directly owns 111,056 shares of the company’s stock, valued at approximately $3,331,680. This represents a 0.91 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 86,578 shares of company stock worth $2,474,440. 7.90% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on DNLI shares. Bank of America upped their target price on shares of Denali Therapeutics from $25.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. HC Wainwright reaffirmed a “buy” rating and set a $90.00 price objective on shares of Denali Therapeutics in a research report on Thursday, November 7th. JPMorgan Chase & Co. dropped their target price on Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Cantor Fitzgerald downgraded Denali Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 7th. Finally, Raymond James restated a “market perform” rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Denali Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.90.

Denali Therapeutics Stock Down 1.6 %

Denali Therapeutics stock opened at $23.32 on Friday. The firm has a market capitalization of $3.36 billion, a PE ratio of -8.45 and a beta of 1.35. Denali Therapeutics Inc. has a 52 week low of $14.56 and a 52 week high of $33.33. The firm’s 50-day simple moving average is $26.85 and its 200 day simple moving average is $24.58.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter in the prior year, the firm earned ($0.72) EPS. On average, research analysts expect that Denali Therapeutics Inc. will post -2.69 EPS for the current fiscal year.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.